QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=248F3DAA0A3B49CFFA500CD72A63A70F;jsessionid=7DCB1D2D5C088C7A35EC5C67FB5DDFA2;jsessionid=733F57D8D86D33CE0DAD132723273468;jsessionid=7538F0254AF4F5582D57778479D4F898;jsessionid=F71535A77E71E64558BA8883E980B605;jsessionid=667CC79AF1298619DC66D4C7350D65B5;jsessionid=3F087CFEFE2E3EE28F7BAE7E5511F371;jsessionid=FFF707F5111CA8CD09F9A5E498D7EB34 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=248F3DAA0A3B49CFFA500CD72A63A70F;jsessionid=7DCB1D2D5C088C7A35EC5C67FB5DDFA2;jsessionid=733F57D8D86D33CE0DAD132723273468;jsessionid=7538F0254AF4F5582D57778479D4F898;jsessionid=F71535A77E71E64558BA8883E980B605;jsessionid=667CC79AF1298619DC66D4C7350D65B5;jsessionid=3F087CFEFE2E3EE28F7BAE7E5511F371;jsessionid=FFF707F5111CA8CD09F9A5E498D7EB34